Oncolys BioPharma Inc. engages in the research, development, manufacture, import, and export of oncolytic viruses, drugs and medicines, and tumour diagnostic agents. More Details
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Oncolys BioPharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2OB's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 2OB underperformed the German Biotechs industry which returned 1.1% over the past year.
Return vs Market: 2OB underperformed the German Market which returned 2.6% over the past year.
Price Volatility Vs. Market
How volatile is Oncolys BioPharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Oncolys BioPharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 2OB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 2OB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 2OB is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: 2OB is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2OB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2OB is overvalued based on its PB Ratio (9x) compared to the DE Biotechs industry average (4.4x).
How is Oncolys BioPharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oncolys BioPharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Oncolys BioPharma's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Oncolys BioPharma competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Oncolys BioPharma performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 2OB is currently unprofitable.
Growing Profit Margin: 2OB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2OB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2OB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2OB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.1%).
Return on Equity
High ROE: 2OB has a negative Return on Equity (-46.64%), as it is currently unprofitable.
How is Oncolys BioPharma's financial position?
Financial Position Analysis
Short Term Liabilities: 2OB's short term assets (¥3.0B) exceed its short term liabilities (¥304.6M).
Long Term Liabilities: 2OB's short term assets (¥3.0B) exceed its long term liabilities (¥420.2M).
Debt to Equity History and Analysis
Debt Level: 2OB's debt to equity ratio (20%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 2OB's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2OB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 2OB has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 31.3% each year
What is Oncolys BioPharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2OB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2OB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2OB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2OB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2OB's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Yasuo Urata (65 yo)
Mr. Yasuo Urata, M.Sc. has been President and Chief Executive Officer of Oncolys BioPharma Inc. since March 2004. Mr. Urata served various executive functions at Japan Tobacco pharmaceutical division (JT P ...
|CEO, President & Representative Director||16.58yrs||no data||3.24% |
|External Auditor||9.08yrs||no data||0.0069% |
|External Director||7.58yrs||no data||no data|
|Vice President||no data||no data||0.87% |
|Outside Auditor||3.58yrs||no data||no data|
|Vice President||no data||no data||0.17% |
|Corporate Auditor||3.58yrs||no data||0.00069% |
Experienced Board: 2OB's board of directors are considered experienced (7.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Oncolys BioPharma Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Oncolys BioPharma Inc.
- Ticker: 2OB
- Exchange: DB
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥25.460b
- Listing Market Cap: JP¥203.883m
- Shares outstanding: 14.45m
- Website: https://www.oncolys.com
Number of Employees
- Oncolys BioPharma Inc.
- Toranomon Towers Office
- 4-1-28 Toranomon
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|4588||TSE (The Tokyo Stock Exchange)||Yes||Common Shares||JP||JPY||Dec 2013|
|2OB||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Dec 2013|
Oncolys BioPharma Inc. engages in the research, development, manufacture, import, and export of oncolytic viruses, drugs and medicines, and tumour diagnostic agents. The company’s product pipeline includes ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/20 22:11|
|End of Day Share Price||2020/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.